For: | Salvadori M. Antineoplastic effects of mammalian target of rapamycine inhibitors. World J Transplant 2012; 2(5): 74-83 [PMID: 24175199 DOI: 10.5500/wjt.v2.i5.74] |
---|---|
URL: | https://www.wjgnet.com/2220-3230/full/v2/i5/74.htm |
Number | Citing Articles |
1 |
Omar Abdel-Rahman, Mona Fouad. Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis. Expert Review of Anticancer Therapy 2014; 14(12): 1529 doi: 10.1586/14737140.2014.953936
|
2 |
Tal Gilboa, Reeval Segel, Sharon Zeligson, Gheona Alterescu, Hilla Ben-Pazi. Ganglioglioma, Epilepsy, and Intellectual Impairment due to Familial TSC1 Deletion. Journal of Child Neurology 2018; 33(7): 482 doi: 10.1177/0883073818767036
|
3 |
Kengo Shimazu, Yuji Tada, Takao Morinaga, Masato Shingyoji, Ikuo Sekine, Hideaki Shimada, Kenzo Hiroshima, Takao Namiki, Koichiro Tatsumi, Masatoshi Tagawa. Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways. BMC Cancer 2017; 17(1) doi: 10.1186/s12885-017-3300-y
|
4 |
Po-Ming Chow, Shing-Hwa Liu, Yu-Wei Chang, Kuan-Lin Kuo, Wei-Chou Lin, Kuo-How Huang. The covalent CDK7 inhibitor THZ1 enhances temsirolimus-induced cytotoxicity via autophagy suppression in human renal cell carcinoma. Cancer Letters 2020; 471: 27 doi: 10.1016/j.canlet.2019.12.005
|
5 |
Omar Abdel-Rahman, Mona Fouad. Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis. Future Oncology 2015; 11(1): 79 doi: 10.2217/fon.14.136
|
6 |
Anna Julie Peired, Alessandro Sisti, Paola Romagnani. Renal Cancer Stem Cells: Characterization and Targeted Therapies. Stem Cells International 2016; 2016: 1 doi: 10.1155/2016/8342625
|